This study is an open-label, multicenter, phase Ia/Ib study. To evaluate the safety, tolerability and preliminary efficacy of IBI363 in subjects with advanced, relapsed or metastatic solid tumors or lymphoma, determine the maximum tolerated dose (MTD) or maximum administered dose (MAD), and thus determine its recommended phase 2 dose (RP2D). Ia A part contains dose escalation phase and PD marker exploration phase. Ia B part contains dose expansion phase. Ib contains dose expansion.
This study is an open-label, multicenter, phase Ia/Ib study. To evaluate the safety, tolerability and preliminary efficacy of IBI363 in subjects with advanced, relapsed or metastatic solid tumors or lymphoma, determine the maximum tolerated dose (MTD) or maximum administered dose (MAD), and thus determine its recommended phase 2 dose (RP2D).